Publicacions en què col·labora amb Julio César de la Torre Montero (7)

2021

  1. Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome

    Clinical Pharmacology and Therapeutics, Vol. 109, Núm. 2, pp. 462-470

2020

  1. Association between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women with Breast Cancer

    JAMA Dermatology, Vol. 156, Núm. 9, pp. 987-991

2018

  1. Correction to: Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling (Breast Cancer Research and Treatment, (2018), 171, 3, (627-634), 10.1007/s10549-018-4855-2)

    Breast Cancer Research and Treatment

  2. Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling

    Breast Cancer Research and Treatment, Vol. 171, Núm. 3, pp. 627-634

  3. Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: A study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial

    Pharmacogenetics and Genomics, Vol. 28, Núm. 11, pp. 245-250

2015

  1. Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): A randomized, noninferiority phase II trialwith a pharmacogenetic analysis

    Oncologist, Vol. 20, Núm. 2, pp. 111-112

2014

  1. Identification of genetic variants associated with capecitabine-induced hand-foot syndrome through integration of patient and cell line genomic analyses

    Pharmacogenetics and Genomics, Vol. 24, Núm. 5, pp. 231-237